<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
<th>Title</th>
<th>Authors/References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EDITORIAL</strong></td>
<td>8040</td>
<td>Progress in elucidating the relationship between <em>Helicobacter pylori</em> infection and intestinal diseases</td>
<td>Fujimori S</td>
</tr>
<tr>
<td><strong>FRONTIER</strong></td>
<td>8047</td>
<td>Orphan patients with inflammatory bowel disease - when we treat beyond evidence</td>
<td>Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Papa A, Rapaccini GL, Gasbarrini A, Armuzzi A</td>
</tr>
<tr>
<td></td>
<td>8058</td>
<td>Analogies between medusa and single port surgery in gastroenterology and hepatology: A review</td>
<td>Mittermair C, Weiss HG</td>
</tr>
<tr>
<td><strong>EXPERT CONSENSUS</strong></td>
<td>8069</td>
<td>Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma</td>
<td>Zhao HT, Cai JQ</td>
</tr>
<tr>
<td><strong>MINIREVIEWS</strong></td>
<td>8103</td>
<td>Artificial intelligence-assisted colonoscopy: A review of current state of practice and research</td>
<td>Taghiakbari M, Mori Y, von Renteln D</td>
</tr>
<tr>
<td></td>
<td>8123</td>
<td>Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification</td>
<td>Xu JX, Wu DH, Ying LW, Hu HG</td>
</tr>
<tr>
<td><strong>ORIGINAL ARTICLE</strong></td>
<td>8138</td>
<td>Impact of intrarectal chromofungin treatment on dendritic cells-related markers in different immune compartments in colonic inflammatory conditions</td>
<td>Kapoor K, Eissa N, Tshikudi D, Bernstein CN, Ghia JE</td>
</tr>
<tr>
<td></td>
<td>8156</td>
<td>Multiparameter magnetic resonance imaging of liver fibrosis in a bile duct ligation mouse model</td>
<td>Liu JY, Ding ZY, Zhou ZY, Dai SZ, Zhang J, Li H, Du Q, Cai YY, Shang QL, Luo YH, Xiao EH</td>
</tr>
</tbody>
</table>
Retrospective Study

8166 Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib

Observational Study

8182 Real-world local recurrence rate after cold polypectomy in colorectal polyps less than 10 mm using propensity score matching

LETTER TO THE EDITOR

8194 Microarray analysis to explore the effect of CXCL12 isoforms in a pancreatic pre-tumor cell model
Miao YD, Wang JT, Tang XL, Mi DH

8199 Progress on global hepatitis elimination targets
Waheed Y
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Ki Mun Kang, MD, PhD, Chairman, Professor, Department of Radiation Oncology, College of Medicine, Gyeongsang National University, 79 Gnagnam-ro, Jinju 52727, South Korea. jsk92@gnu.ac.kr

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79; IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020: Gastroenterology is 19/136.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yan-Xia Xing; Production Department Director: Xiang Li; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS
http://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE
December 21, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2021 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
Progress on global hepatitis elimination targets

Yasir Waheed

ORCID number: Yasir Waheed 0000-0002-5789-4215.

Author contributions: Waheed Y solely contributed to the article.

Conflict-of-interest statement: The authors declare having no conflicts of interest in relation to this publication.

Country/Territory of origin: Pakistan

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report’s scientific quality classification
Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially.

Abstract
In 2016, the World Health Assembly adopted a Global Health Sector Strategy on viral hepatitis, with targets set for the years 2020 and 2030 to achieve hepatitis elimination. The main target of hepatitis elimination strategy is to reduce the incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) by 90% and mortality by 65% in 2030. In last 5 years, the number of people receiving HCV treatment has increased from 1 million to 9.4 million; however, this number is far from the 2030 target of 40 million people receiving HCV treatment. HBV and HCV incidence rates are down from 1.4 million to 1.1 million annual deaths but this is far from the 2030 target of < 0.5 million deaths. The coronavirus disease 2019 pandemic has severely affected the efforts in the fight against hepatitis. No major donor has committed to investing in the fight against hepatitis. Time is running out. There is a need to speed up efforts in the fight against hepatitis to achieve hepatitis elimination by 2030.

Key Words: Hepatitis elimination; Blood donations; Safe injections; Hepatitis B vaccination; Harm reduction

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Citation: Waheed Y. Progress on global hepatitis elimination targets. World J Gastroenterol 2021; 27(47): 8199-8200
URL: https://www.wjgnet.com/1007-9327/full/v27/i47/8199.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i47.8199
and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/

Received: July 13, 2021
Peer-review started: July 13, 2021
First decision: August 19, 2021
Revised: August 24, 2021
Accepted: December 7, 2021
Article in press: December 7, 2021
Published online: December 21, 2021

TO THE EDITOR

I read articles from Tijera et al[1], and Pisano et al[2], on viral hepatitis update, progress, challenges, and ways to elimination. Both articles are discussing important points on viral hepatitis but both are missing the actual progress on hepatitis elimination targets set by World Health Organization (WHO).

In this article, I am presenting the latest data on targets set by the WHO to achieve hepatitis elimination by 2030. In last 5 years, the incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) has decreased from 8 million infections to 3 million infections per year and mortality has decreased from 1.4 million deaths to 1.1 million deaths per year[3]. Only 17 countries had a national hepatitis strategic plans in 2012, but this increased to 124 by 2019[3].

The WHO Global Health Sector Strategy on viral hepatitis has shown five areas in which progress is requested to achieve hepatitis elimination by 2030. These areas are: HBV vaccination, birth dose HBV vaccination, safe injection, harm reduction, and diagnosis and treatment of HBV and HCV[4].

From 2015 to 2020, the worldwide coverage of the third dose of HBV vaccine has increased from 82% to 85% and administration of birth dose of HBV vaccine has increased from 38% to 43%. The number of safe blood donations has increased from 89% to 97% and only 3.9% of injection equipment are still reused. The number of clean syringes given to each person who inject drugs per year has increased from 20 to 33. The HBV diagnosis rate has increased from < 5% to 10% and 22% of diagnosed cases received treatment. The HCV diagnosis rate has increased from < 5% to 21%, and 62% of diagnosed cases received treatment[3,4].

New data shows progress with reference to 2020 hepatitis elimination targets for blood donation screening, HBV and HCV treatments, reduction in drug pricing, and decreasing the incidence of HBV and HCV[3]. However, the 2030 targets of hepatitis elimination are very ambitious and need a strong political and financial commitment [3].

Hepatitis elimination targets needs an investment of US $6 billion per year[3]. No major donor has committed to the fight against hepatitis[3]. Many countries with well-developed hepatitis control programs are lacking financial resources to achieve targets.

The coronavirus disease 2019 (COVID-19) pandemic has severely affected the hepatitis elimination targets. Outpatient departments/liver clinics have remained closed in many countries due to lockdown restrictions. Many countries have spent a major proportional of their health budget on COVID-19 and the nascent viral hepatitis programs are being held back due to a lack of funding[5].

This is the time to put money into the fight against hepatitis and increase HBV and HCV diagnosis and treatment rates[5]. There is a strong need to obtain a cure for HBV and further develop and simplify hepatitis screening tests and make them available in primary health care settings[5]. It is the time to set interim hepatitis elimination targets for 2026 as a milestone towards 2030 targets.

REFERENCES


